| Literature DB >> 35912040 |
Yao Tong1, Zunyi Zhang1, Shusheng Wang1,2,3.
Abstract
Retinal pigment epithelial (RPE) cells form a monolayer between the neuroretina and choroid. It has multiple important functions, including acting as outer blood-retina barrier, maintaining the function of neuroretina and photoreceptors, participating in the visual cycle and regulating retinal immune response. Due to high oxidative stress environment, RPE cells are vulnerable to dysfunction, cellular senescence, and cell death, which underlies RPE aging and age-related diseases, including age-related macular degeneration (AMD). Mitochondria are the powerhouse of cells and a major source of cellular reactive oxygen species (ROS) that contribute to mitochondrial DNA damage, cell death, senescence, and age-related diseases. Mitochondria also undergo dynamic changes including fission/fusion, biogenesis and mitophagy for quality control in response to stresses. The role of mitochondria, especially mitochondrial dynamics, in RPE aging and age-related diseases, is still unclear. In this review, we summarize the current understanding of mitochondrial function, biogenesis and especially dynamics such as morphological changes and mitophagy in RPE aging and age-related RPE diseases, as well as in the biological processes of RPE cellular senescence and cell death. We also discuss the current preclinical and clinical research efforts to prevent or treat RPE degeneration by restoring mitochondrial function and dynamics.Entities:
Keywords: RPE; age-related macula degeneration; aging; cell death; degeneration; mitochondria; senescense
Year: 2022 PMID: 35912040 PMCID: PMC9337215 DOI: 10.3389/fragi.2022.926627
Source DB: PubMed Journal: Front Aging ISSN: 2673-6217
RPE changes during normal aging and AMD.
| RPE changes | References | |
|---|---|---|
| Normal Aging | Loss of melanin granules | ( |
| Lipofuscin accumulation | ( | |
| Decreased RPE cell density and increased RPE cell size and multinucleation |
| |
| Shortening of RPE microvilli |
| |
| Increased BrM thickness and decreased BrM/choroid elasticity | ( | |
| Drusen formation |
| |
| Basal laminar deposit |
| |
| Accumulation of iron |
| |
| RPE secretome changes |
| |
| Modest decrease in RPE phagocytosis |
| |
| AMD | (May) have more cellular senescence |
|
| (May) have more cell death | ||
| Large soft drusen formation |
| |
| Hyper- or hypopigmentation in RPE | ||
| Lipofuscin aggregation in RPE | ( | |
| High variable and thicker RPE layer |
| |
| Shedding, dissociation and sloughing RPE cells (may indicate EMT process) | ||
| More significantly decreased RPE phagocytosis |
| |
| Reduced mitochondrial function | ( | |
| Increased inflammation markers | ||
| RPE secretome changes | ( | |
FIGURE 1RPE changes during aging: Young RPE cell shows elongated microvilli, tight contact with nearby cells, containing plenty of mitochondria, melanin granules and photoreceptor fragments. Aged RPE cell shows larger size, multinucleation, shortened microvilli, decreased mitochondria numbers, loss of melanin granules, decreased phagocytosis, accumulation of lipofuscin and iron, basal laminar deposits, increased BrM thickness and accumulation of drusen.
Mitochondrial changes during normal aging and AMD.
| Mitochondrial changes | References | |
|---|---|---|
| Normal Aging (in general) | Abnormally round shape |
|
| Reduction in mitochondrial number |
| |
| mtDNA mutation, deletion and damage and reduced copy number |
| |
| Lower mitochondrial ATP level |
| |
| Reduced mitochondrial membrane potential |
| |
| Decreased mitophagy |
| |
| Increased mitochondrial ROS level |
| |
| Impaired balance of mitochondrial fission and fusion balance (In most cases, more fission during aging and more fusion in longevity models) | ( | |
| Decreased mitochondrial biogenesis | ||
| RPE Aging | Round or oval in mitochondrial shape | ( |
| Disorganized mitochondrial cristae | ||
| Irregular in mitochondrial size | ||
| Sparse mitochondrial distribution in the cytoplasm | ||
| Reduction in mitochondrial number | ||
| mtDNA damage |
| |
| Lower ATP production | ( | |
| Reduced mitochondrial membrane potential |
| |
| Decreased cytoplasmic Ca2+ concentration | ( | |
| Increased mitochondrial Ca2+ sequestration | ( | |
| Impaired mitochondrial fission and fusion balance |
| |
| AMD | Abnormal mitochondrial shape and size | ( |
| Reduction in mitochondrial number | ( | |
| mtDNA damage | ( | |
| Impaired mitochondrial fission and fusion balance |
| |
| Lower mitochondrial ATP production | ( | |
| Reduced mitochondrial membrane potential |
| |
| Lower basal respiration and maximum respiration | ( | |
FIGURE 2Comparison of mitochondria in young, aged and AMD RPE: (A) Young RPE cell contains numerous mitochondria with long axes, usually oriented from the apical to the basal surfaces of the RPE and are parallel to one another. The mitochondrial cristae are well preserved. Several peroxisomes appeared as small, round, electron-dense organelles. Plenty of melanin granules exist in the cells. (B) In aged RPE cell, mitochondria show membrane disorganization and loss of cristae. Accumulated lipofuscin presents in the cell. Several peroxisomes of various density, shape and size were distributed randomly in the cytoplasm. Less melanin granules appear in the cell. Also, small drusen forms underneath BrM and basal lamina deposits forms in between the cell and BrM. (C) In AMD RPE, advanced mitochondrial alterations occur. Most mitochondria had severe disorganization of membranes that varied from focal to complete loss of cristae. Peroxisomes are clustered and aggregated in the cell. Large and soft drusen forms underneath the BrM.
FIGURE 3Mitochondria changes in RPE senescence: PGAM5 dephosphorylates DRP-1 which promotes mitochondrial fission, which then inhibits the increase of ROS and ATP in RPE cellular senescence; H2O2 and CSE induce increased mitochondrial ROS and membrane potential, also induce decreased ATP level which cause RPE cellular senescence; PGC-1α is a master regulator of mitochondria biogenesis and could reduce ROS level which may inhibit RPE cellular senescence. PGAM5: phosphoglycerate mutase 5; DRP1: dynamin-related protein 1; H2O2: hydrogen peroxide; CSE: cigarette smoke extract; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator-1α; ATP: adenosine triphosphate; ROS: reactive oxygen species; ΔΨm: mitochondrial membrane potential.
FIGURE 4Mitochondria changes in RPE cell death induced by different stressors: A2E and blue light lead to fragmented mitochondria, imbalanced mitochondrial fusion/fission, decreased ATP level, increased ROS level and release of cytochrome C which then induce apoptosis; UV and menadione cause mitochondrial membrane damage, fragmented mitochondria, increased ROS level and release of cytochrome C which then induce apoptosis; H2O2, tBHP and NaIO3 cause fragmented mitochondria and damaged mitochondrial network, and lead to necrosis. NaIO3 also induces decreased mitochondrial membrane potential and increased ROS level, and leads to ferroptosis. High glucose induces mitochondrial membrane damage, fragmented mitochondria and cause ferroptosis; Auranofin causes decreased mitochondrial membrane potential, fragmented, vesiculated and damaged mitochondria, increased ROS level and decreased ATP level which lead to pyroptosis. A2E: N-retinylidene-N-retinyl-ethanolamine; UV: ultraviolet; H2O2: hydrogen peroxide; tBHP: tert-butyl hydroperoxide; NaIO3: sodium iodate; ATP: adenosine triphosphate; ROS: reactive oxygen species; ΔΨm: mitochondrial membrane potential.
Potential therapeutics for RPE Aging and AMD through restoring mitochondrial function.
| Compound | Functions | References |
|---|---|---|
| Humanin | Reduce pro-apoptosis gene expression levels |
|
| Prevent the loss of AMD mitochondria | ||
| Protect oxidative-stress induced RPE cell death and senescence |
| |
| Prevent oxidative stress-induced decrease in mitochondrial bioenergetics | ||
| Increase mitochondrial DNA copy number | ||
| Upregulate the expression of mitochondrial transcription factor A | ||
| Resveratrol | Improve cell viability | ( |
| Decrease ROS level | ||
| Stimulate mitochondrial bioenergetics | ||
| Induce autophagy, pro-survival and specific anti-inflammatory response |
| |
| Suppress choroidal neovascularization |
| |
| Activate SIRT1, a key regulator of cellular senescence, aging and longevity |
| |
| Chrysoeriol | Diminish mitochondrial dysfunction |
|
| Prevent ROS accumulation | ||
| Enhance expression of anti-oxidative genes | ||
| Attenuate oxidative stress-induced mitochondrial membrane potential loss | ||
| Necrostatins | Protect oxidative stress-induced RPE cell death | ( |
| Recover mitochondrial dysfunction and reduce ROS production in response to necroptosis inducer TNFα or acetaminophen | ( | |
| PU-91 | Upregulate PGC-1α |
|
| Increase mtDNA copy number | ||
| Upregulate the genes involved in mitochondrial biogenesis pathway | ||
| Increase mitochondrial membrane potential | ||
| Decrease the level of mitochondrial superoxide | ||
| Upregulate SOD2 expression level | ||
| TPP-Niacin | Ameliorate H2O2-induced Mitochondrial dysfunction and mitochondrial membrane potential reduction |
|
| Enhance the expression of transcription factors (PGC-1α and NRF2) and antioxidant-associated genes (HO-1 and NQO-1) | ||
| ZLN005 | Upregulate of PGC-1α and its associated transcription factors, antioxidant enzymes, and mitochondrial genes |
|
| Increase basal and maximal respiration rates, and spare respiratory capacity | ||
| AICAR, Metformin, Trehalose | Maintain RPE mitochondrial function by activating AMPK pathway and boost autophagy | ( |
| Rapamycin | Inhibit mTOR and activate autophagy | ( |
| Nicotinamide mononucleotide (NMN) | Improve mitochondrial functions including basal respiration, maximal respiration, spare respiratory capacity and ATP production |
|
| Elamipretide | Reduce RPE cell death and senescence. Under phase II clinical trail |
|
| α-Lipoic acid (LA) | Protect against an acute acrolein-induced RPE cell death |
|
| Prevent mitochondrial membrane potential decrease | ||
| Inhibit generation of intracellular oxidants | ||
| Prevent the intracellular SOD decrease | ||
| Protect mitochondrial complex I, II, and III activity | ||
| Increase intracellular total antioxidant power in RPE cells | ||
| Melatonin | Protect human RPE cells against cytotoxic effects of H2O2 |
|
| Protect of mtDNA of ARPE-19 cells against H2O2-induced damage |
| |
| SkQ1 | Prevent progression of retinopathy and suppressed atrophic changes in the RPE cells in the senescence-accelerated OXYS rats | ( |
Abbreviations: RPE, retinal pigmented epithelial; AMD, Age-related macular degeneration; ROS, reactive oxygen species; POS, photoreceptor outer segments; BrM, Bruch’s membrane; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; TGF, transforming growth factor; TCA, tricarboxylic acid; ER, endoplasmic reticulum; ATP, adenosine triphosphate; mtDNA, mitochondrial DNA; NAD, nicotinamide adenine dinucleotide; GTPase, Guanosine triphosphatases; MFN, mitofusins; Opa1, Optic atrophy 1; Drp1, Dynamin-related protein 1; PGC, Peroxisome proliferator-activated receptor gamma coactivator; NRF, nuclear respiratory factors; TOM, translocase of the outer membrane; Pink1, PTEN-induced putative kinase 1; AMPK, Adenosine5′-monophosphate (AMP)-activated protein kinase; LC3, Microtubule-associated protein 1 light chain 3; TEM, transmission electron microscopy; MT/LT, MitoTracker/LysoTracker; PUFA, polyunsaturated fatty acids; UV, ultraviolet; EMT, Epithelial-mesenchymal transition; GA, geographic atrophy; SD-OCT, spectral domain optical coherence tomography; TUNEL, Terminal deoxynucleotidyl transferase dUTP, nick end labeling; iPSC, induced pluripotent stem cell; NLRP3, NLR, Family Pyrin Domain Containing 3; mtHsp, mitochondrial heat shock protein; CFH, Complement factor H; SIRT1, Sirtuin 1; mTOR, mammalian target of rapamycin; NRF2, Nuclear factor erythroid 2-related factor 2; OXPHOS, oxidative phosphorylation; Fis1, Mitochondrial fission 1 protein; CSE, cigarette smoke extract; PGAM5, Phosphoglycerate mutase 5; H2O2, hydrogen peroxide; ΔΨm, Mitochondrial membrane potential; MOMP, mitochondrial outer membrane permeabilization; BCL-2, B-cell lymphoma 2; BAK, BCL-2, antagonist/killer; BAX, BCL-2–associated X; SMAC, Second mitochondria-derived activator of caspase; MPTP, mitochondrial permeability pore; GSDMD, Gasdermin D; CoQH2, ubiquinol; FSP1, Ferroptosis Suppressor Protein 1; GPX4, Glutathione peroxidase 4; A2E, N-retinylidene-N-retinyl-ethanolamine; tBHP, tert-butyl hydroperoxide; NaIO3, sodium iodate; TXNIP, Thioredoxin-interacting protein; Nec-1, Necrostatin-1; RIPK1, Receptor Interacting Serine/Threonine Kinase 1; PPAR; Peroxisome proliferator-activated receptors; TPP, triphenylphosphonium; AICAR, 5-Aminoimidazole-4-carboxamide ribonucleotide; NMN, nicotinamide mononucleotide; LA, α-Lipoic acid; SkQ1, Plastoquinonyl-decyl-triphenylphosphonium.